Chris Sampson

Chris Sampson is an independent researcher based in London. He leads research on health technology assessment, economic evaluation, and broader resource allocation problems. He is a member of the EuroQol Group and an Honorary Associate Professor at the University of Nottingham.

Publications and Insights

• Bulletin: The disputed calculus of life
• Publication: The impact of inflation on incremental costs in HTA
• Insight: NICE’s new cost-effectiveness threshold: Significance, consequences, and unanswered questions
• Publication: The value of cell and gene therapies to the UK economy
• Insight: Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines
• Bulletin: 2025: all change, please
• Insight: Infectious disease: another reason to try Veganuary for the NHS
• Publication: A Framework for Value-aligned Pricing of Combination Therapies
• Insight: Around the World in HTAs: United States – Making HTA Great Again
• Insight: Could Plant-based Diets Transform Health Care Spending?
• Publication: The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
• Insight: Sleepio: Lessons from the Frontier of Digital Therapeutics
• Insight: To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement
• Publication: How is Quality of Life Measured for Health Technology Assessments?
• Publication: Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?
• Publication: How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy
• Publication: The Impact of New Medicines in the NHS: 70 Years of Innovation
• Publication: R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
• Publication: Barriers to Uptake of Minimal Access Surgery in the United Kingdom